Human-Derived Targets for Kidney Disease

Fibrocor Therapeutics is developing potential first-in-class therapies for kidney disease, guided by insights from human kidney tissue. Our discovery approach uses transcriptomic analysis of patient biopsies to identify targets involved in fibroblast activation and excessive collagen deposition, processes that contribute to scar tissue formation and progressive kidney damage.

Our primary focus is kidney allograft fibrosis (KAF), where scarring can impair the function and shorten the lifespan of a transplanted kidney. Although immunosuppressive treatments help control rejection, there remains a need for therapies that address fibrotic damage and preserve long-term transplant function.

Our lead program, FIB992, is being developed to target these fibrotic processes, with the goal of preserving kidney function and extending transplant longevity. Biomarkers and kidney biopsy findings inform our clinical development strategy, helping guide patient selection and the evaluation of treatment effects on kidney tissue.

Alport syndrome and chronic kidney disease (CKD) are our secondary indications, reflecting the potential to apply our approach across kidney diseases in which fibrosis contributes to declining function. Across these priorities, our goal is to slow disease progression and improve long-term outcomes for patients.

Molecular-Clinical interface

Longitudinal biobank samples correlated with fibrotic pathology, clinical outcome.

Tissue-cell-disease specificity

RNA-seq analysis for target discovery

Focus on novel tractable targets

Fibrosis Molecular pathways, genomic association and key biological insights.

Validation of key candidate compounds

Demonstrated activity in preclinical in vivo models of Alport syndrome, autosomal dominant polycystic kidney disease (ADPKD) and kidney fibrosis induced by unilateral ureteral obstruction (UUO).

Superior Drug Profile(s)

First-in-class candidates, Extremely potent, selective, and excellent safety profile and margins

Patient-derived disease driven
insights at the heart of innovation

Thanks to exclusive access to one of the world’s largest fibrosis tissue biobanks containing kidney, liver, and lung biopsies, Fibrocor has been able to gain novel mechanistic insights and identified disease-relevant, druggable targets from long-term biopsies / biobank work into the underlying mechanisms of fibrosis and made significant strides in the field.

These biobanks, which are connected to best-in-class longitudinal medical records, have provided Fibrocor with invaluable patient information for research and development. They underpin our biomarker-driven strategy and have enabled us to identify novel disease targets to develop a robust pipeline of first-in-class therapeutics.

Our exceptional drug candidates have progressed seamlessly into pre-clinical assessment, paving the way for transformative advancements in fibrosis treatment.


Fibrocor Pioneers a Novel Approach

We collaborate with proven scientific experts to ensure the highest scientific rigor and expertise for target validation and candidate identification. We harness the collective knowledge and insights of unique ecosystem to identify disease drivers and assess their novelty, relevance, and drugability. Thorough validation of these targets was performed using cell and animal models, ensuring that only the most promising candidates move forward in our drug discovery pipeline.

We target key mediators of kidney pathology that we identified by interrogating the largest human kidney disease biobank

new-graphic-homepage
Halting disease progression by targeting fibroblast activation and collagen production